• 1
    Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881887.
  • 2
    Vega GL, Adams-Huet B, Peshock R et al. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab 2006;91:44594466.
  • 3
    Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93:S57S63.
  • 4
    Kuk JL, Katzmarzyk PT, Nichaman MZ et al. Visceral fat is an independent predictor of all-cause mortality in men. Obesity (Silver Spring) 2006;14:336341.
  • 5
    McMillan KP, Kuk JL, Church TS, Blair SN, Ross R. Independent associations between liver fat, visceral adipose tissue, and metabolic risk factors in men. Appl Physiol Nutr Metab 2007;32:265272.
  • 6
    Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:10101013.
  • 7
    Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:51595165.
  • 8
    Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003;284:E1065E1071.
  • 9
    Fabbrini E, Magkos F, Mohammed BS et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009;106:1543015435.
  • 10
    Yim JE, Heshka S, Albu J et al. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. Int J Obes (Lond) 2007;31:14001405.
  • 11
    Anderson JW, Schwartz SM, Hauptman J et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother 2006;40:17171723.
  • 12
    Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother 2007;8:17331742.
  • 13
    Tiikkainen M, Bergholm R, Rissanen A et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004;79:2230.
  • 14
    Thomas EL, Makwana A, Newbould R et al. Pragmatic study of orlistat 60 mg on abdominal Obesity. Eur J Clin Nutr 2011 (in press).
  • 15
    Bellido GD. Orlistat reduces the visceral adipose tissue according to the central obesity grade. Int J Obes 2007:S170.
  • 16
    Rolls B and Barnett RA. Volumetrics: Feel Full on Fewer Calories. Harper Collins: New York, 1999.
  • 17
    Smith SR, Lovejoy JC, Greenway F et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metab Clin Exp 2001;50:425435.
  • 18
    Goodpaster BH, Thaete FL, Kelley DE. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 2000;71:885892.
  • 19
    Napolitano A, Miller SR, Murgatroyd PR et al. Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity (Silver Spring) 2008;16:191198.
  • 20
    Gray DS, Bray GA, Gemayel N, Kaplan K. Effect of obesity on bioelectrical impedance. Am J Clin Nutr 1989;50:255260.
  • 21
    Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28: 412419.
  • 22
    DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214E223.
  • 23
    Smith SR, Zachwieja JJ. Visceral adipose tissue: a critical review of intervention strategies. Int J Obes Relat Metab Disord 1999;23:329335.
  • 24
    Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160167.
  • 25
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8:4961.
  • 26
    Karhunen L, Franssila-Kallunki A, Rissanen P et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord 2000;24:15671572.
  • 27
    Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293:28732883.
  • 28
    Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes (Lond) 2008;32:619628.
  • 29
    Ruan XY, Gallagher D, Harris T et al. Estimating whole body intermuscular adipose tissue from single cross-sectional magnetic resonance images. J Appl Physiol 2007;102:748754.
  • 30
    Fabbrini E, Conte C, Magkos F. Methods for assessing intrahepatic fat content and steatosis. Curr Opin Clin Nutr Metab Care 2009;12:474481.
  • 31
    Schwenzer NF, Springer F, Schraml C et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433445.
  • 32
    Stern SE, Williams K, Ferrannini E et al. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005;54:333339.
  • 33
    Myint Swe K, Napolitano A, Miller SR et al. Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens. Obesity (Silver Spring) 2010;18:391396.